IL17A and metabolic dysfunction-associated steatotic liver disease: Lastly, a lack of either IL-17A or IL-17F may be sufficient for an increase in anti-inflammatory and/or immune-regulatory mediators normally inhibited by the IL-17 axis cytokines, such as T regulatory cell expansion and activation, and this accrual could be responsible for protection from NAFLD progression [26].